Calcivis

Year founded 2012
HQ Location Edinburgh
Sector Pharmaceutical / Healthcare
Staff count 22
Total capital raised £9.5m
Founder Adam Christie credits early hiring of top talent and funding from Scotland’s Archangels as key to his scale-up success, helping Calcivis to revolutionise dentistry with its novel tool that diagnoses active tooth decay.
calcivis.com
After working across the whole value chain in big pharmaceutical companies, I was ready to build something of my own.

Adam Christie

Founder & CEO

Starting up with glowing potential

Scottish dental academic Dr Chris Longbottom was killing time in a Baltimore bookshop when a title called Glowing Genes caught his eye. It has a chapter on bioluminescent marine life that uses photo-proteins to signal to each other in the depths of the ocean. These proteins are activated by calcium ions – the same molecules released during active tooth decay.

Longbottom was instantly fascinated. At the time dentists had no way of diagnosing active tooth decay. Instead, they had to make educated guesses, which inevitably led to both under- and over-treatment.

 

Eureka: achieving a world first

This was back in 2008. And Longbottom presented his idea to LUX, a biotechnology company based in Edinburgh.

Adam Christie, a highly experienced pharmaceutical executive and a director of LUX, was intrigued by the project.

“Chris’s idea was a true light-bulb moment”, says Christie. “I went away and did my research and talked to some dentists. They were all intrigued by the potential. They told me it would be a “first” and could have a massive impact on reducing the number of patients getting cavities.”

LUX did the early development work in partnership with the University of Dundee and filed a patent application. But soon the company turned its focus to the oil and gas sector and by 2010 further development had stalled.

Hiring the right people is one of the most difficult things. For a new company, it’s make or break.

Adam Christie, Calcivis

 

Getting the team together

But Christie, who had over 20 years’ experience in pharmaceuticals and start-ups, knew the idea could be a blockbuster and treat a real unmet need. “So I went to the Lux board and asked that if I were able to get this funded, would they be interested in taking a stake in a new business in return for the IP.” They agreed.

“Over the next 18 months I put a company together, secured the investment and by 2012 I started the business,” says Christie.

He raised £1.2m in capital from Archangels, an Edinburgh-based business angels syndicate. “I’d already done a little bit of work with them, they’re one of the oldest business angel networks around. A very organised, professional group.”

With this money Christie could pay his new team. They were all experts from the pharmaceutical manufacturing, regulation and finance sectors who had initially joined as consultants. He emphasises the importance of these early hires. “Hiring the right people is one of the most difficult things. For a new company, it’s make or break.”

 

Looking to a bright future

Christie has raised £9.5m so far, comprising £7m in equity and £2.5m from European Horizon 2020 and Innovate UK grants. This funded a working prototype, a sales team and funding for the UK launch. The cash is also paving the way for the company to break into the all-important US market.

“The biggest opportunity in the dental market is the US. For us, we believe a conservative turnover estimate would be around £300m a year,” he says.

Christie is already getting “glowing” reviews from happy patients. “They love it. They can see glowing images of hot spots on their teeth where they are losing calcium. Then their dentist gives them a preventative treatment to avoid a potential cavity.”

Right now as he’s getting his team ready for US regulatory approval Christie says: “It’s an exciting time. But it’s also nerve-racking as we’re getting ready for US Food and Drug Administration inspections of our manufacturing supply chain. There’s a lot going on but it’s exhilarating.”


Key Metrics

£300m

Conservative turnover estimate a year

1 second

Time to detect tooth decay with calcivis tool

500m+

Primary dental examinations each year in Europe and the US

Sources of capital
Government Support
  • European Commission Horizon 2020 SME Instrument programme
  • Innovate UK

Related Stories

ToucanBox
ToucanBox is among the UK’s fastest-growing education technology businesses thanks to early backing from the co-founders of Innocent Drinks and equity investment from BGF. Read more...
Longitude
An impressive 55.9% annual average revenue growth rate between 2012 and 2015 helped confirm Longitude’s place on the FT1000 fastest-growing businesses in Europe list. But it has done so entirely from cashflow, rather than relying on external financial support. Read more...
V-Nova
V-Nova has ambitions to walk alongside Silicon Valley’s winners, using its PERSEUS technology to help media and entertainment companies monetise unmet consumer demand for high-definition video. Read more...
The Office Group
A committed co-founder partnership fostered The Office Group’s reputation and track record, opening the doors to key investors and powering its meteoric growth in the London office market. Read more...
Way To Blue
Meeting the needs of its international clients from Hollywood film premieres to best-selling Christmas toys at Hamleys, integrated communications agency Way To Blue has gradually scaled its full-service offering across the globe, investing in agencies, platforms and most importantly, people. Read more...
Cocoon
Hardware and software specialist Cocoon is helping people feel safe in their homes with its surveillance solutions, and its same-name device is generating admissible evidence to combat crime. Read more...